Saarilahti Kauko, Kajanti Mikael, Kouri Mauri, Aaltonen Leena-Maija, Franssila Kaarle, Joensuu Heikki
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):986-95. doi: 10.1016/s0360-3016(03)00736-3.
To investigate the association between the cancer cell proliferation fraction and the risk of recurrence in laryngeal cancer patients treated without systemic therapy.
Paraffin-embedded tumor samples from 90 laryngeal cancer patients were stained for cyclin A and the Ki-67 antigen by immunohistochemistry. The patients were treated with partial or total laryngectomy followed by postoperative radiotherapy to a total dose of 50 Gy or greater. The median follow-up time was 91 months (minimum 48 months).
High cyclin A expression (>19% positive cancer cell nuclei, the highest tertile) was associated with a high rate of locoregional tumor recurrence and unfavorable disease-free and overall survival as compared with cases with a lower expression (p = 0.025, 0.032, and 0.042, respectively). In a multivariate analysis, high cyclin A expression was an independent predictor of poor disease-free survival (RR 2.4, 95% CI 1.2-4.9, p = 0.013) and overall survival (RR 2.1, 1.2-3.6, p = 0.012), together with a poor Karnofsky's performance status and the presence of positive margins at surgery. Ki-67 expression was not an independent predictor of survival, but cancers with high Ki-67 expression (>34% nuclei positive, the highest tertile) recurred more frequently locoregionally when treated with split-course radiotherapy than when treated with a continuous course of therapy (p = 0.035), whereas the presence of a planned split did not influence the frequency of locoregional recurrences when Ki-67 expression was lower (p = 0.93).
Cancer cell cyclin A expression is a novel predictive factor for outcome in laryngeal cancer treated with surgery and postoperative radiotherapy. Planned gaps in the radiotherapy course are deleterious in patients with a high proliferative fraction, and immunostaining for the Ki-67 antigen may be useful in identification of such patients.
探讨在未接受全身治疗的喉癌患者中,癌细胞增殖分数与复发风险之间的关联。
对90例喉癌患者的石蜡包埋肿瘤样本进行免疫组织化学染色,检测细胞周期蛋白A(cyclin A)和Ki-67抗原。患者接受部分或全喉切除术,术后放疗总剂量为50 Gy或更高。中位随访时间为91个月(最短48个月)。
与细胞周期蛋白A低表达的病例相比,高细胞周期蛋白A表达(>19%阳性癌细胞核,最高三分位数)与局部区域肿瘤复发率高、无病生存期和总生存期不良相关(p分别为0.025、0.032和0.042)。在多变量分析中,高细胞周期蛋白A表达是无病生存期差(风险比2.4,95%可信区间1.2 - 4.9,p = 0.013)和总生存期差(风险比2.1,1.2 - 3.6,p = 0.012)的独立预测因素,同时还与卡诺夫斯基表现状态差和手术切缘阳性有关。Ki-67表达不是生存的独立预测因素,但高Ki-67表达(>34%细胞核阳性,最高三分位数)的癌症在接受分段放疗时比接受连续放疗时局部区域复发更频繁(p = 0.035),而当Ki-67表达较低时,计划分段的存在并不影响局部区域复发的频率(p = 0.93)。
癌细胞周期蛋白A表达是手术和术后放疗治疗喉癌预后的一个新的预测因素。放疗疗程中的计划间隙对增殖分数高的患者有害,对Ki-67抗原进行免疫染色可能有助于识别此类患者。